Compare VanEck Semiconductor ETF (SMH) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? VanEck Semiconductor ETF trades at $556.46 (market cap $71.21B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: VanEck Semiconductor ETF is far larger — about 9.5× Spyre Therapeutics Inc. Common Stock's market cap, and VanEck Semiconductor ETF is more actively traded (7,965,961 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 102 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SMH | SYRE | |
|---|---|---|
Market Cap | $71.21B | $7.52B |
Volume | 7,965,961 | 1,441,031 |
52-Week High | $668.91 | $108.92 |
52-Week Low | $325.10 | $22.18 |
Typical Hold Time | 102 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH, the VanEck Semiconductor ETF, trades at $564.74, down 4.44% over 24 hours amid sector volatility. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while RSI_6 at 26.18 suggests potential oversold conditions. Recent news highlights strong 2026 performance, with the ETF up around 69% year-to-date, outpacing major holdings like Nvidia, and benefiting from AI-driven semiconductor demand and industry consolidation such as AMD's acquisition of World Labs.
The outlook for SMH remains positive due to robust sector growth and AI expansion, though risks include high concentration in top holdings and sensitivity to tech sector swings. Investors should weigh the ETF's historical outperformance against potential volatility from trade tensions and macroeconomic factors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
